| An overview of clinical decision support systems: benefits, risks, and strategies for success RT Sutton, D Pincock, DC Baumgart, DC Sadowski, RN Fedorak, ... NPJ digital medicine 3 (1), 17, 2020 | 1468 | 2020 |
| Training disrupted: Practical tips for supporting competency-based medical education during the COVID-19 pandemic AK Hall, MT Nousiainen, P Campisi, JD Dagnone, JR Frank, KI Kroeker, ... Medical teacher 42 (7), 756-761, 2020 | 214 | 2020 |
| Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical review KM Reich, RN Fedorak, K Madsen, KI Kroeker World Journal of Gastroenterology: WJG 20 (17), 4934, 2014 | 172 | 2014 |
| Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort C Ma, RN Fedorak, GG Kaplan, LA Dieleman, SM Devlin, N Stern, ... Alimentary pharmacology & therapeutics 45 (9), 1232-1243, 2017 | 168 | 2017 |
| Patients with IBD are exposed to high levels of ionizing radiation through CT scan diagnostic imaging: a five-year study KI Kroeker, S Lam, I Birchall, RN Fedorak Journal of clinical gastroenterology 45 (1), 34-39, 2011 | 120 | 2011 |
| Treatment of ulcerative colitis with adalimumab or infliximab: long‐term follow‐up of a single‐centre cohort N Gies, KI Kroeker, K Wong, RN Fedorak Alimentary pharmacology & therapeutics 32 (4), 522-528, 2010 | 118 | 2010 |
| Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn's disease: real-world experience from a multicenter cohort study C Ma, RN Fedorak, GG Kaplan, LA Dieleman, SM Devlin, N Stern, ... Inflammatory bowel diseases 23 (5), 833-839, 2017 | 116 | 2017 |
| The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti‐TNF use: a time‐trend study KM Reich, HJ Chang, A Rezaie, H Wang, KJ Goodman, GG Kaplan, ... Alimentary pharmacology & therapeutics 40 (6), 629-638, 2014 | 108 | 2014 |
| Effect of proinflammatory interleukins on jejunal nutrient transport J Hardin, K Kroeker, B Chung, DG Gall Gut 47 (2), 184-191, 2000 | 104 | 2000 |
| Systematic review of nutrition screening and assessment in inflammatory bowel disease S Li, M Ney, T Eslamparast, B Vandermeer, KP Ismond, K Kroeker, ... World journal of gastroenterology 25 (28), 3823, 2019 | 74 | 2019 |
| Anti-TNF therapy within 2 years of Crohn's disease diagnosis improves patient outcomes: a retrospective cohort study C Ma, CL Beilman, VW Huang, DK Fedorak, KI Kroeker, LA Dieleman, ... Inflammatory bowel diseases 22 (4), 870-879, 2016 | 70 | 2016 |
| Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab A Hu, PG Kotze, A Burgevin, W Tan, A Jess, PS Li, K Kroeker, B Halloran, ... Clinical Gastroenterology and Hepatology 19 (7), 1366-1376. e2, 2021 | 68 | 2021 |
| An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ Digit Med. 2020; 3: 17 RT Sutton, D Pincock, DC Baumgart, DC Sadowski, RN Fedorak, ... Published online, 2020 | 58 | 2020 |
| Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease C Ma, V Huang, DK Fedorak, KI Kroeker, LA Dieleman, BP Halloran, ... Alimentary pharmacology & therapeutics 40 (9), 1044-1055, 2014 | 58 | 2014 |
| Prevalence of Epstein–Barr virus in a population of patients with inflammatory bowel disease: a prospective cohort study MS Linton, K Kroeker, D Fedorak, L Dieleman, RN Fedorak Alimentary pharmacology & therapeutics 38 (10), 1248-1254, 2013 | 57 | 2013 |
| Increased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel disease JF Turcotte, K Wong, SJ Mah, LA Dieleman, D Kao, K Kroeker, B Claggett, ... Clinical and translational gastroenterology 3 (7), e19, 2012 | 57 | 2012 |
| Outpatient ulcerative colitis primary anti-TNF responders receiving adalimumab or infliximab maintenance therapy have similar rates of secondary loss of response C Ma, V Huang, DK Fedorak, KI Kroeker, LA Dieleman, BP Halloran, ... Journal of clinical gastroenterology 49 (8), 675-682, 2015 | 56 | 2015 |
| Does the level of reproductive knowledge specific to inflammatory bowel disease predict childlessness among women with inflammatory bowel disease? VW Huang, HJ Chang, KI Kroeker, KJ Goodman, KM Hegadoren, ... Canadian Journal of Gastroenterology and Hepatology 29, 95-103, 2015 | 53 | 2015 |
| Preoperative ustekinumab treatment is not associated with increased postoperative complications in Crohn’s disease: a Canadian multi-centre observational cohort study HH Shim, C Ma, PG Kotze, CH Seow, H Al-Farhan, AK Al-Darmaki, ... Journal of the Canadian Association of Gastroenterology 1 (3), 115-123, 2018 | 49 | 2018 |
| Crohn’s disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study C Ma, V Huang, DK Fedorak, KI Kroeker, LA Dieleman, BP Halloran, ... Journal of Crohn's and Colitis 8 (11), 1454-1463, 2014 | 49 | 2014 |
